Marino Stram & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Marino Stram & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,023	Closed	-$206K	–	285
2021 Q2	$206K	Buy	+1,023	New	+$214K	0.05%	240
2019 Q2	–	Sell	-23	Closed	-$4K	–	563
2019 Q1	$4K	Hold	23	–	–	﹤0.01%	436
2018 Q4	$4K	Hold	23	–	–	﹤0.01%	378
2018 Q3	$4K	Hold	23	–	–	﹤0.01%	374
2018 Q2	$4K	Buy	+23	New	+$3.56K	﹤0.01%	373

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marino Stram & Associates's VRTX Position: Q3 2021 in Review

Marino Stram & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 1,023 shares — an estimated $206K sold.

Marino Stram & Associates first reported a position in VRTX in Q2 2018 and held it in 5 quarters. The position peaked at $206K in Q2 2021. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Marino Stram & Associates reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Marino Stram & Associates sold 1,023 Vertex Pharmaceuticals shares in Q3 2021, an estimated $206K.
Marino Stram & Associates first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Marino Stram & Associates's Vertex Pharmaceuticals position peaked at $206K in Q2 2021.
933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Marino Stram & Associates's 13F filing for Q3 2021, filed 14 Oct 2021.